Triple-combined hypolipidaemic therapy in familial hypercholesterolaemia: clinical cases
Background. The prevalence of heterozygous familial hypercholesterolaemia (HeFH) comprises 1 per 250 people. The risk of premature cardiovascular disease (CVD) is 20 times higher in HeFH patients among the general population. CVD develops in HeFH patients under 20 years of age, and they usually do n...
Saved in:
Main Authors: | Svetlana A. Chepurnenko, Galina V. Shavkuta, Alina V. Safonova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Ministry of Healthcare of the Russian Federation. “Kuban State Medical University”
2021-10-01
|
Series: | Кубанский научный медицинский вестник |
Subjects: | |
Online Access: | https://ksma.elpub.ru/jour/article/view/2618 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetic and Bioequivalence Study of the Two-component Drug Product "Ezetimibe + rosuvastatin" (JSC "Sanofi-aventis group", Russia): Resuts and Experience with the Use of Enzymatic Hydrolysis in the Analysis of Samples
by: A. L. Khokhlov, et al.
Published: (2023-02-01) -
NEW OPPORTUNITIES FOR PREVENTIVE THERAPY WITH STATINS DURING CHD PATIENTS’ REHABILITATION, WITH CLINICAL SIGNS OF MODERATE CHF: EFFECTIVENESS OF ROSUVASTATIN AND EZETIMIBE
by: N. I. Tarasov, et al.
Published: (2016-06-01) -
Population Pharmacokinetics and Pharmacodynamics with Enterohepatic Recirculation of Co-Medication of Rosuvastatin and Ezetimibe
by: An H, et al.
Published: (2025-06-01) -
Isogenic induced pluripotent stem cell line ICGi036-A-1 from a patient with familial hypercholesterolaemia, derived by correcting a pathogenic variant of the gene LDLR c.530C>T
by: A. S. Zueva, et al.
Published: (2025-04-01) -
ADVANTAGES AND NOVELTY OF CLINICAL APPLICATION OF THE TRIPLE COMBINATION FOR ARTERIAL HYPERTENSION WITH DYSLIPIDEMIA: ACE INHIBITOR PERINDOPRIL WITH ROSUVASTATIN AND INDAPAMIDE
by: M. L. Maksimov, et al.
Published: (2017-08-01)